Bone metastases: Approaches to management

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 11, 2001, Pages 28-34

  Janjan, Nora ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

ADVANCED CANCER; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER HORMONE THERAPY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; FRACTURE; HUMAN; LUNG CANCER; PAIN ASSESSMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT PLANNING;

EID: 0034856776     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.25444     Document Type: Conference Paper

References (47)

1. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
2. The palliation of symptomatic osseous metastases
3. The clinical course of bone metastases from breast cancer
4. Bone destruction in cancer
5. Bisphosphonates in the management of breast cancer
6. Uses and abuses of bisphosphonates
7. The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials
8. Pain syndromes in patients with cancer
9. Does cancer survival differ for older patients?
10. Management of metastatic bone pain
11. Radiotherapeutic management of pain
12. Management of pain
13. Spinal axis metastases
14. The emerging role of bisphosphonates in the prevention of bone metastases
15. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1.1-bisphosphonate (APD)
16. A randomised controlled trial of intravenous clodronate in metastatic bone disease and pain
17. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized, controlled trial
18. Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases
19. Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone
20. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
21. Overview of bisphosphonates
22. Relationships between biochemical and symptomatic response in a doubleblind trial of pamidronate for metastatic bone disease
23. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonates (APD) treatment
24. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia
25. Singledose intravenous therapy with pamidronate for the treatment of hypercalcaemia of malignancy; Comparison of 30-, 60-, and 90-mg dosages
26. Bisphosphonates in the treatment of disorders of mineral metabolism
27. Bisphosphonates: Mechanisms of action and clinical use in osteoporosis-an update
28. Irradiation of bone metastases in breast cancer patients: A randomised study with 1 year follow-up
29. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis
30. The head and neck radiotherapy questionnaire: A morbidity/quality of life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer
31. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases
32. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain
33. A randomised trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain
34. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: Randomized comparison with a multifraction schedule over 12 months of patient follow-up
35. The effect of a single fraction compared to multiple fractions on painful bone metastases: A global analysis of the Dutch Bone Metastasis Study
36. Primary cancer treatmentantineoplastic treatment in pain management
37. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
38. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases
39. An emerging respect for palliative care in radiation oncology
40. Pain and its treatment in outpatients with metastatic cancer
41. Cancer pain management by radiotherapists: A survey of radiation therapy oncology group physicians
42. Cancer facts and figures
43. Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis
44. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer
45. Advanced breast cancer: Use of resources and cost implications
46. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast
47. Medical resource utilization and costs in patients with metastatic breast cancer